This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2006;295:2836-2838.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

While scientists who study conditions such as cancer, heart disease, or stroke can present alarming statistics to highlight a need for funding for their research, those who study rare diseases can find it hard to compete for research dollars. But rare does not mean unimportant, according to the National Institutes of Health (NIH), which announced it will devote $71 million to launch the first clinical studies of its Rare Diseases Clinical Research Network.

More than 20 studies are expected to open in the next few months at about 50 sites in the United States and other countries.

The Rare Diseases Clinical Research Network is enrolling patients in more than a dozen studies on certain rare disorders. Trials for other rare conditions are expected to begin in the near future.

Coordinated primarily by the Office of Rare Diseases and the National Center for Research Resources at the NIH, . . . [Full Text of this Article]

A LOW PROFILE

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rare childhood diseases: how should we respond?
Zurynski et al.
Arch. Dis. Child. 2008;93:1071-1074.
ABSTRACT | FULL TEXT  

On Beyond Zebra: Understanding Rare Diseases
Collard
Chest 2007;131:644-646.
FULL TEXT  

Rare Diseases, Orphan Drugs, and Orphaned Patients
Scheindlin
Mol. Interv. 2006;6:186-191.
FULL TEXT